This Week in Cardiology — Jun 15, 2026

Welcome to This Week in Cardiology. This week we're covering 9 notable papers spanning interventional cardiology and device updates, strategies for optimizing medical therapy and risk stratification, and a look at managing special populations with unmet needs. Let's dive in.

We'll start in the cath lab and the operating room, with updates on renal denervation, coronary interventions, and the ongoing debate in structural heart disease. First, from the *Journal of the American Heart Association*, we have the 3-year durability data from the SPYRAL HTN-ON MED trial of radiofrequency renal denervation [3]. In this prespecified final follow-up, patients with uncontrolled hypertension who received renal denervation had statistically significant and durable reductions in both 24-hour ambulatory and office systolic blood pressure through 36 months compared to a sham control group. The treatment difference for 24-hour ambulatory systolic BP was minus 4.7 millimeters of mercury. This was achieved with a similar antihypertensive medication burden between the groups at 3 years. The study also confirmed a durable safety profile for the procedure, providing more long-term evidence for this device-based approach to hypertension.

Staying with interventions, a major trial in *Circulation* tested a novel strategy for treating de novo coronary lesions [8]. Researchers randomized over 3300 participants to either a strategy using a new sirolimus-eluting balloon with provisional stenting, or to systematic implantation of a drug-eluting stent. The primary endpoint was target vessel failure at one year, a composite of cardiac death, target vessel MI, and clinically driven target vessel revascularization. In the primary intention-to-treat analysis, the sirolimus-eluting balloon strategy was non-inferior to systematic stenting. However, this result comes with two important caveats. First, clinically driven target vessel revascularization was more frequent in the balloon group, at 3.3% versus 2.1%. Second, a sensitivity analysis on the per-protocol population did not confirm non-inferiority. So while the overall strategy shows promise, the higher revascularization rate and mixed statistical findings suggest we need to watch for the 5-year data before drawing firm conclusions.

And for patients with aortic stenosis, the debate over the best approach continues. The *European Heart Journal* hosts a great debate on whether surgical aortic valve replacement, or SAVR, should remain the first choice for patients with a life expectancy beyond 5 years [6]. While guidelines increasingly favor transcatheter aortic valve implantation, or TAVI, in older patients, the authors note that randomized trial data confirming equivalent outcomes largely stops at 5 years. They argue that concerns about higher rates of pacemaker requirement and paravalvular regurgitation with TAVI, along with insufficient long-term durability data, may become more relevant over a longer time horizon, potentially favoring SAVR for patients expected to live longer. This paper summarizes the key pros and cons that clinicians and heart teams grapple with daily when advising patients.

Next, we'll turn to medical management, with important new data on lifelong lipid-lowering, antithrombotic choices in PAD, and a call to action on a key biomarker in heart failure. A powerful study in the *European Heart Journal* from the SAFEHEART registry underscores the profound benefit of early treatment for familial hypercholesterolaemia [7]. This observational study followed children with genetically confirmed FH, their unaffected siblings, and their affected parents. The children with FH started cholesterol-lowering medication at a median age of 14.5 years, compared to 36 years for their parents. The result was a dramatic difference in cumulative LDL cholesterol burden. By age 39, the cardiovascular event rate in the early-treated children was just 0.3%, compared to 5.2% in their late-treated parents, and similar to the 0.0% rate in their unaffected relatives. These findings provide compelling support for viewing FH as a paediatric condition that requires early detection and treatment to normalize long-term risk.

For patients with peripheral artery disease, choosing the right antithrombotic regimen is a constant balance. A new network meta-analysis in the *Journal of the American Heart Association*, including over 44,000 participants from 17 trials, provides some clarity [4]. Compared to aspirin monotherapy, several regimens were associated with a lower risk of major adverse cardiac events, including clopidogrel, aspirin plus low-dose rivaroxaban, and aspirin plus ticagrelor. However, regimens containing rivaroxaban or clopidogrel with aspirin were associated with a higher risk of major bleeding. The authors conclude that clopidogrel plus cilostazol or clopidogrel monotherapy might represent the most balanced strategy for reducing ischemic events without significantly increasing bleeding risk.

Finally in this section, a review in the *European Heart Journal* argues that we may be underutilizing a simple, powerful risk marker in heart failure: albuminuria [9]. The authors note that albuminuria is present in nearly half of all heart failure patients and is an independent predictor of incident heart failure and adverse outcomes. Unlike guidelines for diabetes or chronic kidney disease, heart failure guidelines do not universally recommend routine screening. The review highlights that several guideline-directed therapies, including SGLT2 inhibitors and finerenone, reduce albuminuria, and this reduction is associated with better outcomes. This suggests albuminuria is not just a marker, but a modifiable factor, and routine screening could help clinicians better stratify risk and target therapies.

Our final theme this week focuses on specific patient groups where evidence can be sparse. First, a new scientific statement from the American Heart Association, published in *Circulation*, aims to standardize how we measure cardiovascular events in oncology trials [1]. With the rapid expansion of new cancer therapies, understanding cardiotoxicity is critical. However, progress has been hampered by inconsistent endpoint definitions. This statement provides a detailed framework for systematically selecting and defining cardiovascular endpoints like heart failure, myocarditis, and thrombosis in cancer trials. By harmonizing data collection, this effort aims to improve risk stratification and patient safety in the growing field of cardio-oncology.

For patients with myocardial infarction with nonobstructive coronary arteries, or MINOCA, and Takotsubo syndrome, who often suffer from significant anxiety and stress, a trial in the *Journal of the American Heart Association* explored a potential non-pharmacologic therapy [2]. This randomized trial tested an internet-delivered cognitive behavioral therapy program against a wait-list control. For the primary outcome, which was a composite of normalized stress and anxiety levels, the treatment group showed a positive trend but the result was not statistically significant. However, secondary analyses did show a treatment effect on anxiety normalization and on symptoms as continuous measures. Exploratory analyses also suggested that patients with Takotsubo syndrome may derive greater benefit, though this requires further study.

Finally, from the *Journal of the American Heart Association*, a large Swedish registry study examined sex differences after aortic valve surgery for infective endocarditis [5]. The study included over 2500 patients and found that women undergoing surgery were older and had more comorbidities. Despite this, after adjusting for these baseline differences, women had higher net survival compared to men. The most sobering finding, however, was the profound loss of life expectancy for both sexes, particularly in younger patients. A 50-year-old woman, for example, had a loss of life expectancy of 15.5 years. This highlights the devastating toll of severe infective endocarditis and reinforces the critical need for early diagnosis and optimized care.

If you only have time for one paper this week, make it the SAFEHEART study on familial hypercholesterolaemia in the *European Heart Journal* [7]. Its powerful, multi-generational cohort data provides some of the clearest evidence to date that treating FH from childhood can effectively normalize cardiovascular risk, reinforcing the paradigm of FH as a pediatric condition requiring early detection and intervention.

Here are the key takeaways from this week in Cardiology. First, for familial hypercholesterolaemia, the SAFEHEART study provides compelling observational evidence that starting cholesterol-lowering therapy in childhood dramatically reduces lifetime LDL burden and nearly eliminates cardiovascular events by young adulthood, strongly supporting early screening and treatment [7]. Second, in hypertension, 3-year data from SPYRAL HTN-ON MED show that radiofrequency renal denervation provides a durable blood pressure lowering effect compared to a sham-crossover control, with a good long-term safety profile [3]. Third, for de novo coronary lesions, a strategy of a sirolimus-eluting balloon with provisional stenting was non-inferior to systematic DES for target vessel failure at one year in the intention-to-treat analysis, but this was not confirmed in the per-protocol analysis and came at the cost of more frequent target vessel revascularization [8]. Fourth, in peripheral artery disease, a new network meta-analysis suggests that while dual pathways with aspirin plus rivaroxaban or ticagrelor reduce ischemic events, they increase bleeding, and that clopidogrel monotherapy or with cilostazol may offer a more balanced risk-benefit profile [4]. And finally, a major review reminds us that albuminuria is a potent and modifiable risk marker in heart failure, and its routine measurement could help refine risk stratification and guide therapy with agents like SGLT2 inhibitors [9].

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.